Zydus Lifesciences Q1 FY27 profit drops 36% to ₹940 crore despite 22% revenue rise
Synopsis
Zydus Lifesciences grew revenue by 22% in Q1 FY27 — but profit collapsed 36% to ₹940 crore as EBITDA margins fell nearly 770 basis points to 24.1%. The divergence between top-line strength and bottom-line weakness is the defining story of this quarter, and the market's muted reaction suggests investors are betting on a margin recovery.
Key Takeaways
Zydus Lifesciences reported a 35.9% YoY fall in net profit to ₹940 crore in Q1 FY27 .
Revenue from operations rose 22% to ₹8,017 crore , up from ₹6,574 crore in Q1 FY26 .
EBITDA declined 7.6% to ₹1,930 crore ; EBITDA margin contracted to 24.1% from 31.8% .
Shares traded at ₹1,126 post-results, up 0.63% , signalling a muted market reaction.
The stock has gained 25.43% over the past six months and 23.20% on a year-to-date basis.
Zydus Lifesciences on Tuesday, 11 August 2025, reported a sharp 35.9 per cent year-on-year decline in consolidated net profit for Q1 FY27, even as revenue from operations surged to a new quarterly high. The Ahmedabad-based drugmaker posted a net profit of ₹940 crore for the April–June 2025 quarter, down from ₹1,467 crore in Q1 FY26, according to its stock exchange filing.
Revenue Up, Margins Under Pressure
Revenue from operations climbed 22 per cent year-on-year to ₹8,017 crore, compared with ₹6,574 crore in the corresponding quarter a year ago — a robust top-line showing. However, the bottom line told a different story. EBITDA fell 7.6 per cent to ₹1,930 crore from ₹2,089 crore, and the EBITDA margin contracted sharply to 24.1 per cent from 31.8 per cent in Q1 FY26 — a compression of nearly 770 basis points. The divergence between revenue growth and profit decline points to rising costs eating into operating leverage.
Market Reaction
Despite the earnings miss on profitability, markets reacted with relative calm. Shares of Zydus Lifesciences were trading at ₹1,126 following the results announcement, up 0.63 per cent (or ₹7) from the previous close. The muted selloff suggests investors may have already priced in margin pressure, or are choosing to focus on the company's strong revenue trajectory.
Stock Performance Across Time Frames
The stock has delivered mixed returns depending on the horizon. Over the past five trading sessions, it gained 1.41 per cent (₹15.70). On a one-month basis, however, the stock slipped 0.52 per cent (₹5.90). The medium-term picture is more encouraging: over six months, Zydus shares have rallied 25.43 per cent, adding ₹228.40 in value, and are up 23.20 per cent on a year-to-date basis, gaining ₹212.25.
About Zydus Lifesciences
Zydus Lifesciences, formerly known as Cadila Healthcare, was founded in 1952 and rebranded in 2022. Headquartered in Ahmedabad and led by Chairman Pankaj R. Patel, the company operates in more than 50 countries with over 30 manufacturing facilities worldwide. Its diversified portfolio spans generic medicines, active pharmaceutical ingredients (APIs), vaccines, biosimilars, and specialty products. Through subsidiary Zydus Wellness, it also owns consumer brands including Glucon-D, Sugar Free, Complan, Nycil, and Everyuth.
With revenue momentum intact but margins under strain, the coming quarters will test whether Zydus can restore profitability without sacrificing its top-line growth.
Point of View
But it could also reflect complacency. If cost pressures persist into Q2 FY27, the six-month stock rally of 25% could face a sharper test than today's muted session suggests.
NationPress
11 Aug 2026
Frequently Asked Questions
What were Zydus Lifesciences' Q1 FY27 earnings results?
Zydus Lifesciences reported a net profit of ₹940 crore in Q1 FY27, down 35.9% from ₹1,467 crore in Q1 FY26. Revenue from operations, however, rose 22% to ₹8,017 crore during the same period.
Why did Zydus Lifesciences' profit fall despite higher revenue?
Profitability came under pressure due to rising costs, which compressed the EBITDA margin to 24.1% from 31.8% a year earlier. EBITDA itself fell 7.6% to ₹1,930 crore, indicating that cost growth outpaced revenue expansion.
How did Zydus Lifesciences shares react to the Q1 results?
Shares of Zydus Lifesciences were trading at ₹1,126, up 0.63% (₹7) after the results were announced, suggesting investors were largely unfazed by the profit decline.
What is Zydus Lifesciences' stock performance over the past year?
On a year-to-date basis, the stock has risen 23.20% (₹212.25), and over six months it has gained 25.43% (₹228.40). Over one month, however, it was marginally lower by 0.52%.
What businesses does Zydus Lifesciences operate?
Zydus Lifesciences operates across generic medicines, APIs, vaccines, biosimilars, and specialty products. Through its subsidiary Zydus Wellness, it also owns consumer brands such as Glucon-D, Sugar Free, Complan, Nycil, and Everyuth, giving it a diversified presence across healthcare and consumer segments.
